Gregory Lip

Gregory Lip serves as an Honorary Professor in Applied Health Sciences at the University of Liverpool, with active clinical and research engagement in cardiovascular medicine. His work bridges clinical practice with extensive research output spanning over 1,400 publications and 24 major projects since 1994, focusing on high-impact areas of cardiac rhythm disorders and thrombosis.

His primary research domains include atrial fibrillation pathophysiology, hypertension management, heart failure therapeutics, and antithrombotic strategies, with specific emphasis on ethnic variations in vascular disease presentation and treatment response. Lip leads a laboratory investigating thrombosis mechanisms and vascular biology in stroke, while also examining psychophysiological aspects of cardiovascular disease and stakeholder perceptions of anticoagulation management.

Recent scholarly activity demonstrates consistent high-impact contributions, including co-authorship of the 2024 ESC Guidelines for atrial fibrillation management and numerous studies addressing global implementation challenges of anticoagulation therapy. His work spans quantitative clinical research, molecular investigations of genetic polymorphisms, and qualitative analyses of patient experiences across diverse healthcare settings including Brazil and Thailand.

Lip actively supervises doctoral candidates in cardiovascular epidemiology and experimental thrombosis research while directing significant projects such as TREATS-AF (an MRC-funded educational intervention study in Thailand) and industry-sponsored investigations into oral anticoagulants. His laboratory group maintains active collaborations with the British Heart Foundation and pharmaceutical partners including Bristol Myers Squibb and Daiichi Sankyo.

Professional activities include leadership in the NIHR Global Health Research Group on Atrial Fibrillation Management and the EURObservational Research Programme's AF-GEN-UK registry, reflecting his commitment to both clinical innovation and real-world evidence generation in cardiovascular care.